Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07504796 · ClinicalTrials.gov registry record · Phase 4
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
A Phase 4 study, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT07504796 is a Phase 4 study that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 90 participants.
The verdict
NCT07504796, a Phase 4 study, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity of immune-related adverse events.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Relatlimab
- DEVICE Signatera genome MRD assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-04-13 |
| Est. Completion | 2031-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07504796
The ClinicalTrials.gov registry entry for NCT07504796 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT07504796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07504796 about?
NCT07504796 is a clinical study titled "ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab". The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity of...
What is the current status of trial NCT07504796?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2026-04-13. Estimated completion is 2031-05.
What interventions are being tested in trial NCT07504796?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Relatlimab (DRUG), Signatera genome MRD assay (DEVICE).
Who is sponsoring clinical trial NCT07504796?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.